Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

AbbVie Partners with Sarah Cannon Research Institute to Enhance Diverse Cancer Trials

AbbVie, the Chicago-based pharmaceutical giant, has announced a strategic partnership with Nashville's Sarah Cannon Research Institute (SCRI) to bolster its community-based clinical trials for novel cancer treatments. This collaboration aims to increase diversity in oncology trials and improve access to cutting-edge therapies for patients across the United States.

NoahAI News5/29/2025

Novartis Secures $1.7 Billion Acquisition of Regulus Therapeutics After Intense Bidding War

In a significant move that has caught the attention of the pharmaceutical industry, Novartis has emerged victorious in a competitive bidding war to acquire Regulus Therapeutics for $1.7 billion. The deal, which was finalized in late April, centers around Regulus' promising kidney disease drug candidate, farabursen, and marks a substantial investment in the growing field of rare disease treatments.

NoahAI News5/29/2025

GSK's Antibiotic Breakthrough: Tebipenem HBr Shows Promise in Late-Stage Study

GSK, the British pharmaceutical giant, has announced a significant milestone in the development of a novel antibiotic for complicated urinary tract infections (cUTIs). The company's late-stage clinical trial for tebipenem HBr, an oral carbapenem antibiotic, has met its primary endpoint, potentially paving the way for a new treatment option in the fight against antimicrobial resistance.

NoahAI News5/29/2025

GSK and Scynexis Resume Brexafemme Trial Amid Payment Dispute

Scynexis has announced the resumption of its phase 3 MARIO study for Brexafemme (ibrexafungerp), a month after the FDA lifted its clinical hold on the antifungal drug. This development has sparked a disagreement between Scynexis and pharmaceutical giant GSK over milestone payments, highlighting the complexities of their partnership in commercializing the treatment.

NoahAI News5/29/2025

Abbott Secures FDA Approval for Tendyne Mitral Valve Replacement System, Expanding Treatment Options for Heart Patients

Abbott has received Food and Drug Administration (FDA) approval for its Tendyne transcatheter mitral valve replacement system, marking a significant advancement in cardiac care. The device is designed to treat patients with severe mitral annular calcification who are not candidates for open heart surgery or transcatheter mitral valve repair.

NoahAI News5/29/2025

GLP-1 Prescriptions for Weight Loss Soar Amid Supply Challenges and Cost Concerns

The pharmaceutical industry is witnessing a dramatic surge in the adoption of GLP-1 (glucagon-like peptide-1) drugs for weight loss, despite recent supply shortages and high prices. This trend is reshaping the obesity treatment landscape and creating significant opportunities for drug manufacturers.

NoahAI News5/29/2025

PepGen Halts Duchenne Muscular Dystrophy Program Following Phase 2 Trial Disappointment

PepGen, a Boston-based biotech company, has announced the termination of its Duchenne muscular dystrophy (DMD) research and development activities following disappointing results from a phase 2 clinical trial. The decision marks a significant setback in the pursuit of effective treatments for this debilitating genetic disorder.

NoahAI News5/29/2025

Digital Sleep Clinic Dreem Health Expands Coverage to Humana Members, Aims to Revolutionize Sleep Care

Dreem Health, a digital sleep clinic platform, has announced a new partnership with Humana, marking its latest expansion in coverage among major insurers. This move signals a growing trend in the healthcare industry towards leveraging technology to address sleep disorders and improve overall sleep quality for millions of Americans.

NoahAI News5/29/2025

Abridge Expands AI Documentation Capabilities with Pediatric Well Visit Template

Artificial intelligence (AI) clinical documentation startup Abridge has unveiled a new medical record template specifically designed for pediatric primary care well visits, marking a significant advancement in the company's mission to streamline healthcare documentation.

NoahAI News5/29/2025

InflaRx Discontinues Vilobelimab Study for Rare Skin Disease, Shifts Focus to Oral C5aR1 Blocker

German biopharmaceutical company InflaRx has announced the discontinuation of its Phase III trial for vilobelimab in the treatment of pyoderma gangrenosum (PG), a rare inflammatory skin disorder. The decision comes after an independent data monitoring committee recommended halting the study due to futility, marking a significant setback for the company's rare disease program.

NoahAI News5/28/2025

AbbVie's Allergan Cuts Staff Following Marketing Setback, Amid Broader Industry Challenges

AbbVie's aesthetics division, Allergan, is set to lay off 202 employees at its Irvine, California site, according to a recent Worker Adjustment and Retraining Notification (WARN) update. The workforce reduction, scheduled to take effect on July 22, primarily targets sales, data engineering, and product management roles. This move comes in the wake of a failed marketing campaign and broader market pressures affecting the pharmaceutical giant.

NoahAI News5/28/2025

Former Chinook Board Member Indicted in $3.2B Novartis Acquisition Insider Trading Scandal

The pharmaceutical industry has been rocked by allegations of insider trading related to Novartis' $3.2 billion acquisition of Chinook Therapeutics in 2023. The U.S. Department of Justice (DOJ) has charged five individuals, including a former Chinook board member, with securities fraud and conspiracy in connection with the high-profile buyout.

NoahAI News5/28/2025

«1...61 62 63...67 »